The lung cancer detection and screening market is experiencing a growing demand due to the increasing number of high-risk individuals and the need for early detection. Traditional methods such as CT scans are often limited by their accessibility and availability, hindering timely diagnoses. OncoSwab is a venture developing a point-of-care test that can be performed in various healthcare settings. Their non-invasive approach, targeting cancer-driven mutations through nasal fluid collection, eliminates the need for specialized medical personnel and is suited for self-testing and telemedicine. By leveraging the direct link between nasal and bronchial epithelia, OncoSwab surpasses the limitations of invasive blood samples for early-stage detection, ensuring quicker results and heightened sensitivity. By making screening more accessible to patients and not expecting the opposite to occur, their goal is to help make early lung cancer detection the rule.